Adempas is the first and only medicine approved by the FDA to treat adults with:
- Chronic thromboembolic pulmonary hypertension (CTEPH) (WHO Group 4) treated with surgery but who continue to have high pulmonary blood pressure (persistent) or it comes back after surgery (recurrent), or that cannot be treated with surgery (inoperable)
- Pulmonary arterial hypertension (PAH) (WHO Group 1)
The Adempas clinical studies included mostly patients with WHO functional class II–III symptoms. It is not known if Adempas is safe and effective in children.
WHO=World Health Organization
HOW FAR MIGHT ADEMPAS TAKE YOU?
Adempas can help increase your ability to walk farther and improve some of your symptoms. Patients with PAH and CTEPH taking Adempas were able to walk farther in a 6-minute walk distance (6MWD) test than patients taking a placebo (no Adempas) in the following studies:
Adempas and PAH
Change in 6MWD at the end of a 12-week study of 443 adults with PAH (WHO Group 1).
50% more patients who took Adempas improved their WHO functional class compared to patients who took a placebo (no Adempas).
21% of Adempas patients showed WHO functional class improvement vs 14% of placebo patients.
Adempas and CTEPH
Change in 6MWD at the end of a 16-week study of 261 adults with CTEPH (WHO Group 4).
50% as many patients who took Adempas improved their WHO functional class compared to patients who took a placebo (no Adempas).
33% of Adempas patients showed WHO functional class improvement vs 15% of placebo patients.